Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

American Academy of Stem Cell Physicians To Hold Board Examination at Upcoming Annual Meeting

February 28, 2023 By Cade Hildreth, Founder & President Leave a Comment

American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications on June 2-4, 2023m in Miami, FL

MIAMI, February 26, 2023 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]

Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure

February 28, 2023 By Cade Hildreth, Founder & President Leave a Comment

HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).

Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.

Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]

The European Innovation Council (EIC) awards the AcouSort project AcouSome SEK 26 million to develop groundbreaking technology for exosome-based diagnostics

February 25, 2023 By Cade Hildreth, Founder & President Leave a Comment

August 13, 2022, Lund, Sweden – Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give us ‘status reports’ on organs such as the brain and heart, as well as give us vital information on tumor diseases, infectious diseases, pregnancy and stem cell conditions. EIC has announced that it granted AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort’s partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. [Read more…]

New Super-Potent Topical Exosome Cosmetics Product, Distributed in UAE by Great Look Medical Supplies, to be Unveiled at Dubai Derma 2023 Conference March 1st- 3rd

February 17, 2023 By Cade Hildreth, Founder & President Leave a Comment

ROCHESTER, NY and DUBAI, UAE, Feb. 17, 2023 – On March 1, Resiliélle Cosmetics, LLC and Regenerelle Biotherapeutics will unveil their new Resiliélle brand topical exosome cosmetics product manufactured by Regenerelle and exclusively distributed worldwide by Resiliélle. Resiliélle’s product will set a new standard for skin rejuvenation and lustrous hair. For optimal results, aesthetics professionals may use Resiliélle topically after microneedling or laser treatments. Resiliélle believes that the use of our topical exosome cosmetics will allow MedSpa, Dermatology and Plastic Surgery patients to use Resiliélle topical exosome cosmetics that have been developed to help patients to Leap Back In Time™ — At Any Age.™ [Read more…]

Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors

February 15, 2023 By Cade Hildreth, Founder & President Leave a Comment

FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]